Skip to main content

Advertisement

Log in

Altered MHC class I antigens in tumors

  • Review
  • Published:
International Journal of Clinical and Laboratory Research

Abstract

MHC class I antigens are lost or downregulated in invasive tumors compared with autologous normal tissues. This is observed in most of the newly induced experimental tumors analyzed if they are cloned before passaging in vivo. Similarly, this is observed in 40%-90% of human tumors using the available panel of anti-HLA class I monoclonal antibodies. In both systems the tumor populations are heterogeneous for H-2/HLA expression and composed of clones that express different amounts of MHC class I antigens. This heterogeneity may have a profound influence on tumor behavior, considering the role that MHC antigens play in T and natural killer cell-mediated responses. It is possible that the tumor escape mechanisms from T and natural killer cells select variants that express a particular MHC class I altered phenotype. We review the MHC changes detected in different experimental as well as human tumors and demonstrate the relevance of these altered H-2/HLA tumor phenotypes for implementing immunotherapeutic strategies based on T or natural killer cellmediated responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Garrido F, Festenstein H, Schirrmacher V. Further evidence for derepression of H-2 and Ia like specificities of foreign haplotypes in mouse tumour cell lines. Nature 1976; 261:705.

    Article  PubMed  CAS  Google Scholar 

  2. Garrido F, Festenstein H. Expression of H-2K, H-2D and Ia region products of foreign haplotypes on mouse tumour cells. Folia Biol (Praha) 1976; 1:391.

    Google Scholar 

  3. Garrido F, Pérez M, Torres M. Absence of four H-2d antigenic specificities in an H-2d sarcoma. J Immunogenet 1979; 6:83.

    Article  PubMed  CAS  Google Scholar 

  4. Townsend A, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza cleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44:959.

    Article  CAS  Google Scholar 

  5. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329:506.

    Article  PubMed  CAS  Google Scholar 

  6. Momburg F, Neefjes JJ, HÄmmerling GJ. Peptide selection by MHC-encoded TAP transporters. Curr Opin Immunol 1994; 6:32.

    Article  PubMed  CAS  Google Scholar 

  7. Festenstein H, Garrido F. MHC antigens and malignancy. Nature 1986; 3220:502.

    Article  Google Scholar 

  8. Festenstein H, Schmidt W. Variation in MHC antigenic profiles of tumor cells and its biological effects. Immunol Rev 1981; 60:85.

    Article  PubMed  CAS  Google Scholar 

  9. Kaklamanlis L, Hill A. MHC loss in colorectal tumours: evidence for immunoselection? Cancer Surv 1992; 13:155.

    Google Scholar 

  10. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia following MHC DNA-mediated cell transformation. Nature 1984; 311:750.

    Article  PubMed  CAS  Google Scholar 

  11. Tanaka K, Isselbacher KJ, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985; 228:26.

    Article  PubMed  CAS  Google Scholar 

  12. Mialdea MJ, Gaforio JJ, Pérez M, Garrido F. Effect of MHC class I transfection on local tumor growth and metastasis capacity in a H-2 negative clone of a chemically induced fibrosarcoma. Int J Cancer 1992; 52:153.

    Article  PubMed  CAS  Google Scholar 

  13. Pollack MS, Livingston PO, Fogh J, Carey TE, Oettgen HF, Dupont SO. Genetically appropriate expression of HLA and DR (IA) alloantigens on human melanoma cell lines. Tissue Antigens 1980: 15:249.

    Article  PubMed  CAS  Google Scholar 

  14. Csiba A, Whitwell HL, Moore M. Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer 1984; 50:699.

    PubMed  CAS  Google Scholar 

  15. Lopez Nevot MA, Garcia E, Pareja E, Bonal FJ, Martín J. RuizCabello F, Garrido F. Differential expression of HLA class I and II antigens between primary and metastatic melanomas. J Immunogenet 1986; 130: 219.

    Article  Google Scholar 

  16. Lopez Nevot MA, Esteban F, Ferrón A, Gutierrez J, Oliva MR.Romero C, Huelin C, Ruiz-Cabello F, Garrido F. HLA class I gene expression on human primary tumours and autologous metastasis: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989: 59:221.

    PubMed  CAS  Google Scholar 

  17. Garrido F, Klein E. MHC antigen expression. I. Human tumors. Semin Cancer Biol 1991; 2:1.

    Google Scholar 

  18. Garrido F. The biological implications of the abnormal expression of histocompatibility antigens on murine and human tumors. In: David C, ed. Gene complex, genes, molecules, function. Bar Harbor, Maine: Plenum 1987: Nato ASI series, 144:623.

    Google Scholar 

  19. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14:619.

    Article  PubMed  CAS  Google Scholar 

  20. Gumperz J, Parham P. The enigma of the natural killer cell. Nature 1995; 378:245.

    Article  PubMed  CAS  Google Scholar 

  21. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today 1996; 17:86.

    Article  PubMed  CAS  Google Scholar 

  22. Garrido F, Schirrmacher V, Festenstein H. Studies on H-2 specificities on mouse tumour cells by a new microradioassay. J Immunogenet 1977; 4:15.

    Article  PubMed  CAS  Google Scholar 

  23. Perez M, Garrido A, Algarra I, Garrido F. Different H-2 phenotypes in clones derived from a new BALB/c solid tumor. Its relevance for local tumor growth. Immunologia 1985; 4:60.

    CAS  Google Scholar 

  24. Perez M. Garrido A. Algarra I, Caballero A, Delgado C. Collado MD, Fernandez Cruz E, Garrido F. H-2 antigens and tumorassociated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumor; their influence on the generation in vitro and in vivo of the specific anti-tumor immune response. Exp Clin Immunogenet 1989; 6:204.

    PubMed  CAS  Google Scholar 

  25. Algarra I, Gaforio JJ, Garrido A, Mialdea MJ, Perez M, Garrido F. Heterogeneity of MHC-class I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis. Int J Cancer 1991; 6 [Suppl]: 73.

    Article  CAS  Google Scholar 

  26. Algarra I, öhlen C, Perez M. Ljunggren HG, Klein G. Garrido F, Karre K. NK sensitivity and lung clearance of MHC-class Ideficient cells within a heterogeneous fibrosarcoma. Int J Cancer 1989; 44:675.

    Article  PubMed  CAS  Google Scholar 

  27. Van Waes C, Monach PA, Urban JL, Wortzel RD, Schreiber H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens 1996; 47:399.

    PubMed  Google Scholar 

  28. Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984; 34:567.

    Article  PubMed  CAS  Google Scholar 

  29. Garrido F, Ruiz-Cabello F. Cabrera T, Perez-Villar JJ. Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997; 18, 2:89.

    Article  PubMed  CAS  Google Scholar 

  30. Katzav S, De Baetselier P, Tartakousky B, Feldman M, Segal S. Alteration in major histocompatibility complex phenotypes of mouse cloned T10 sarcoma cells: association with shifts from non-metastatic to metastatic cells. 1983; 71:317.

    CAS  Google Scholar 

  31. Garrido F. HLA and cancer. Tissue antigens 1996; 47:361.

    Article  PubMed  CAS  Google Scholar 

  32. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F. Stern PL. Natural history of HLA expression during tumor development. Immunol Today 1993; 10:491.

    Article  Google Scholar 

  33. Garrido F, Cabrera T, Lopez Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995; 67:155.

    PubMed  CAS  Google Scholar 

  34. Garrido F, Cabrera T, Accola RS, Bensa JC, Bodmer W, Dohr G, Drenou B, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, KageshitaT, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades C, Salvaneschi L, Stern PL, Ziegler A. HLA and cancer. In: Charron D, ed. HLA. Genetic diversity of HLA. Functional and medical implications. Sèvres, France: EDK; 1997; (in press).

    Google Scholar 

  35. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG. Differences in the antigen recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340.

    Article  PubMed  CAS  Google Scholar 

  36. Alberti S, Herzenberg LA. DNA methylation prevents transfection of genes for specific surface antigens. Proc Natl Acad Sci USA 1988;85:8391.

    Article  PubMed  CAS  Google Scholar 

  37. Maschek U, Pulm W, Segal S, Hammerling GJ. Major histocompatibility complex class I genes in murine fibrosarcoma IC9 are down regulated at the level of the chromatin structure. Mol Cell Biol 1989; 9:3136.

    PubMed  CAS  Google Scholar 

  38. Boucraut J, Guillaudeux T, Alizadeh M, Boretto J, Chimini G, Malecaze F, Semana G, Fauchet R, Pontarotti P, Le Bouteiller P. HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR. Immunogenetics 1993; 38:117.

    Article  PubMed  CAS  Google Scholar 

  39. Henseling U, Schmidt W, Scholler HR, Gruss P, Hatzopoulos AK. A transcription factor interacting with the class I gene enhancer is inactive in tumorigenic cell lines which suppress major histocompatibility complex class I genes. Mol Cell Biol 1990; 10:4100.

    PubMed  CAS  Google Scholar 

  40. Blanchet O, Bourge JF, Zinszner H, Tatari Z, Degos L, Paul P. DNA binding of regulatory factors interacting with MHC-class-I gene enhancer correlates with MHC-class-I transcriptional level in class-I-defective cell lines. Int J Cancer 1991 ; [Suppl]6:138.

    Article  CAS  Google Scholar 

  41. Blanchet O, Bourge JF, Zinszner H, Israel A, Kourilsky P, Dausset J, Degos L, Paul P. HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc Natl Acad Sci USA 1992; 89:3488.

    Article  PubMed  CAS  Google Scholar 

  42. Van’t Verr LJ, Beijersbergen RL, Bernards R.N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J 1993; 12:195.

    Google Scholar 

  43. Liu X, Ge R, Westmoreland S, Cooney AJ, Tsai SY, Tsai MJ, Ricciardi RP. Negative regulation by the R2 element of the MHC class I enhancer in adenovirus-12 transformed cells correlates with high levels of COUP-TF binding. Oncogene 1994; 9:2183.

    PubMed  CAS  Google Scholar 

  44. Ge R, Liu X, Ricciardi RP. E1A oncogene of adenovirus-12 mediates trans-repression of MHC class I transcription in Ad5/Ad l2 somatic hybrid transformed cells. Virology 1994; 203:389.

    Article  PubMed  CAS  Google Scholar 

  45. Howcroft TK, Richardon JC, Singer DS. MHC class I gene expression is negatively regulated by the proto-oncogene,c-jun. EMBO J 1993; 12:3163.

    PubMed  CAS  Google Scholar 

  46. Versteeg R. Noordermeer IA. Krüse-Wolters M. Ruiter DJ. Schrier PI,c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 1988, 7:1023.

    PubMed  CAS  Google Scholar 

  47. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restifo NP, Herlyn M, Rosenberg SA. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1990; 153:1225.

    Google Scholar 

  48. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real FX, Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996; 47:372.

    PubMed  CAS  Google Scholar 

  49. Andersson M, Paabo S, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985; 43:215.

    Article  PubMed  CAS  Google Scholar 

  50. Korner H, Burgert HG. Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein a T lymphoma cell line. J Virol 1994; 68:1442.

    PubMed  CAS  Google Scholar 

  51. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 1994; 152: 2736.

    PubMed  CAS  Google Scholar 

  52. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 1993; 151:4455.

    PubMed  CAS  Google Scholar 

  53. Rosa F, Berissi H, Weissenbach J, Maroteaux L, Fellous M, Revel M. The B2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferons. EMBO J 1983; 2:239.

    PubMed  CAS  Google Scholar 

  54. D’Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991; 87:284.

    Article  PubMed  CAS  Google Scholar 

  55. Bicknell DC, Rowan A, Bodmer WF. Beta2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 1994; 91:4751.

    Article  PubMed  CAS  Google Scholar 

  56. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177:265.

    Article  PubMed  CAS  Google Scholar 

  57. Cromme FV, Bommel PF van, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Heimerhorst TJ, Stukart MJ. Meijer CJ. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994; 69:1176.

    PubMed  CAS  Google Scholar 

  58. Cromme FV, Airey J, Heeemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJLM, Walboomers JMM. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335.

    Article  PubMed  CAS  Google Scholar 

  59. Townsed A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989; 7:601.

    Google Scholar 

  60. DeMars R, Rudersdorf R, Chang C, Petersen J, Strandtmann J, Korn N, Sidwell B, Orr HT. Mutations that impair a posttranscriptional step in expression of HLA-A and B antigens. Proc Natl Acad Sci USA 1985; 82:8183.

    Article  PubMed  CAS  Google Scholar 

  61. Hosken NA, Bevan MJ. Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science 1990; 248:367.

    Article  PubMed  CAS  Google Scholar 

  62. Cerundolo V, Alexander J, Anderson K, Lamb C, Cresswell A, McMichael A, Gotch F, Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 1990; 345:449.

    Article  PubMed  CAS  Google Scholar 

  63. Spies T, DeMars R. Restored expression of major histocompatibility molecules by gene transfer putative peptide transporter. Nature 1991; 351:323.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Algarra, I., Collado, A. & Garrido, F. Altered MHC class I antigens in tumors. Int J Clin Lab Res 27, 95–102 (1997). https://doi.org/10.1007/BF02912442

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02912442

Key words

Navigation